Literature DB >> 18570170

Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.

Asim F Tarabar1, Robert S Hoffman, Lewis Nelson.   

Abstract

INTRODUCTION: Citalopram overdose may produce bradycardia, QT prolongation, and torsades de pointes (TdP). A cardiotoxic metabolite may be responsible for the delayed onset of cardiotoxicity. Although some authorities recommend a minimum of 24 hours of observation following citalopram overdose, a recent analysis suggested that dysrhythmias rarely occur beyond 13 hours post-ingestion. We present a case of citalopram overdose with a substantially delayed onset of cardiac toxicity. CASE REPORT: A 36-year-old woman complained of shakiness, numbness in the arms, and palpitations that began approximately 32 hours after ingesting 50 (20-mg) tablets of citalopram. Her initial vital signs were: blood pressure, 84/44 mmHg; pulse, 102-150/minute; respirations, 17/min; temperature, 99.3 degrees F (37.3 degrees C). Her initial ECG showed sinus rhythm with a prolonged corrected QT interval (572 msec) with paroxysmal, self-limited runs of wide-complex tachycardia that appeared multifocal in nature. Approximately 20 minutes after presentation, she experienced self-terminating TdP, with transient hypotension and loss of consciousness. Her serum citalopram concentration (33 hours post-ingestion) was 477 ng/mL (therapeutic: 40-110 ng/mL); desmethylcitalopram concentration was 123.2 ng/mL (therapeutic: 14-40 ng/mL). She was treated with magnesium and lidocaine, and her corrected QT interval remained abnormal for 24 hours after presentation. DISCUSSION: Citalopram overdose can produce life-threatening cardiac toxicity with a clinical onset that may be delayed beyond a routine observation period of 6 hours. Once the QT interval is prolonged, it seems prudent to prolong the observation period.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570170      PMCID: PMC3550142          DOI: 10.1007/bf03160963

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  15 in total

1.  Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.

Authors:  Harry J Witchel; Vijay K Pabbathi; Giovanna Hofmann; Ashok A Paul; Jules C Hancox
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

2.  Symptoms and signs of severe citalopram overdose.

Authors:  L Grundemar; B Wohlfart; C Lagerstedt; F Bengtsson; G Eklundh
Journal:  Lancet       Date:  1997-05-31       Impact factor: 79.321

3.  Citalopram toxicity.

Authors:  M Personne; H Persson; E Sjöberg
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

4.  Citalopram overdose--review of cases treated in Swedish hospitals.

Authors:  M Personne; G Sjöberg; H Persson
Journal:  J Toxicol Clin Toxicol       Date:  1997

5.  Citalopram-induced bradycardia and presyncope.

Authors:  G K Isbister; F H Prior; A Foy
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

6.  Comparative toxicity of citalopram and the newer antidepressants after overdose.

Authors:  C A Kelly; N Dhaun; W J Laing; F E Strachan; A M Good; D N Bateman
Journal:  J Toxicol Clin Toxicol       Date:  2004

7.  Studies on acute toxicity and drug levels of citalopram in the dog.

Authors:  V Boeck; K F Overø; O Svendsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-03

Review 8.  Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.

Authors:  J Hyttel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

Review 9.  Overview of the safety of citalopram.

Authors:  Charles B Nemeroff
Journal:  Psychopharmacol Bull       Date:  2003

10.  Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

View more
  19 in total

1.  Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose.

Authors:  Geoffrey K Isbister; Lena E Friberg; Stephen B Duffull
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

2.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.

Authors:  Nikunjkumar Patel; Barbara Wiśniowska; Masoud Jamei; Sebastian Polak
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

4.  The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of Poisoning.

Authors:  Müjgan Büyükdeligöz; Nil Hocaoğlu; Kubilay Oransay; Yeşim Tunçok; Şule Kalkan
Journal:  Balkan Med J       Date:  2015-07-01       Impact factor: 2.021

5.  Depression, Obstructive Sleep Apnea and Psychosocial Health.

Authors:  Shazia Jehan; Evan Auguste; Seithikurippu R Pandi-Perumal; Jolaade Kalinowski; Alyson K Myers; Ferdinand Zizi; Madhu G Rajanna; Girardin Jean-Louis; Samy I McFarlane
Journal:  Sleep Med Disord       Date:  2017-10-27

Review 6.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

7.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

8.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

9.  Drug-specific risk of severe QT prolongation following acute drug overdose.

Authors:  Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini
Journal:  Clin Toxicol (Phila)       Date:  2020-04-07       Impact factor: 4.467

10.  Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocaine.

Authors:  Emiliano J Sanchez; Robert P Hayes; John T Barr; Kevin M Lewis; Brian N Webb; Arun K Subramanian; Mark S Nissen; Jeffrey P Jones; Eric A Shelden; Barbara A Sorg; Michael Fill; James O Schenk; Chulhee Kang
Journal:  Drug Alcohol Depend       Date:  2013-07-19       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.